{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-105807","form_type":"8-K","ticker":"FBLG","cik":"0001958777","company_name":"FibroBiologics, Inc.","filed_at":"2025-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.697345+00:00","generated_at":"2026-05-17T16:49:51.553951+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"FibroBiologics receives Nasdaq MVLS deficiency notice; 180-day cure period to Feb 2026","bullets":["Nasdaq notified FibroBiologics on Aug 4, 2025 that its MVLS fell below the $35M minimum for continued listing.","Company has until Feb 2, 2026 to regain compliance by having MVLS close at $35M+ for 10 consecutive business days.","No immediate impact on listing; stock continues trading on Nasdaq Capital Market under symbol FBLG.","If compliance is not regained by Feb 2, 2026, Nasdaq may initiate delisting, subject to appeal.","Company will monitor MVLS and consider available options to address the deficiency."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-105807","json":"https://secwatch.observer/filing/0000950170-25-105807.json","markdown":"https://secwatch.observer/filing/0000950170-25-105807.md","text":"https://secwatch.observer/filing/0000950170-25-105807.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1958777/000095017025105807/0000950170-25-105807-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1958777/000095017025105807/fblg-20250725.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T16:49:51.553951+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0e45dd0d531791c236d092c4f019aa21b412f0dd","claim":"FibroBiologics, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).","evidence_excerpt":"August 4, 2025, FibroBiologics, Inc. (the “Company”) received a notification letter from the Listing Qualifications Staff (the \"Staff\") of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it does not meet the requirement in Nasdaq Listing Rule 5550(b)(2) to maintain a minimum Market Value of Listed Securities (“MVLS”) of $35.0 million that is required for continued listing on The Nasdaq Capital Market (the “Notice”). The Notice has no immediate impact on the listing of the Company’s common stock, which will continue to be listed and traded on The Nasdaq Capital Market subject","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1958777/000095017025105807/0000950170-25-105807-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"market value"},{"label":"Rules","value":"5550(b)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}